The disclosure provides compositions comprising water and ultrafine bubbles, and optionally non-gaseous solutes. The disclosure also provides methods of making and using such compositions.

The disclosure provides compositions comprising water and ultrafine bubbles, and optionally non-gaseous solutes. The disclosure also provides methods of making and using such compositions.

A fluidic oscillator includes at least one inlet port (57) in communication with at least two outlets (61) via a nozzle region and two outlet conduits (58, 62), the two outlet conduits being separated from each other by a splitter region. Each outlet conduit includes a resonance chamber (60) in fluid communication with the conduit. The resonance chambers contribute to controlling the oscillation of the device. The fluidic oscillator is operatable in an acoustic switching mode.

A fluidic oscillator includes at least one inlet port (57) in communication with at least two outlets (61) via a nozzle region and two outlet conduits (58, 62), the two outlet conduits being separated from each other by a splitter region. Each outlet conduit includes a resonance chamber (60) in fluid communication with the conduit. The resonance chambers contribute to controlling the oscillation of the device. The fluidic oscillator is operatable in an acoustic switching mode.

A method for improving stability and/or absorption of one or more biologically active agents including preparing formulations wherein a biologically active agent is dispersed using a homogenizer and/or a nanofluidizer; and optionally: i) enriching the formulation; and/or ii) delivering the formulations to a subject whereby the biologically active agent is absorbed by said subject, and/or iii) testing the formulation to identify suitable dosing ranges using computational modeling of biomolecular pathways to determine at least one feature selected from absorption in a cell, saturation of a cell, and potential toxicity in a cell, and/or iv) testing the formulation by monitoring with a low impact, minimally intrusive heart rate variability monitoring to enable rapid determination of neurological and physiological effects of a dosage, establishing dosing levels of the biologically active agent, and/or v) defining the corresponding metabolic effects of the dosage of the biologically active agent on the subject.

A method for improving stability and/or absorption of one or more biologically active agents including preparing formulations wherein a biologically active agent is dispersed using a homogenizer and/or a nanofluidizer; and optionally: i) enriching the formulation; and/or ii) delivering the formulations to a subject whereby the biologically active agent is absorbed by said subject, and/or iii) testing the formulation to identify suitable dosing ranges using computational modeling of biomolecular pathways to determine at least one feature selected from absorption in a cell, saturation of a cell, and potential toxicity in a cell, and/or iv) testing the formulation by monitoring with a low impact, minimally intrusive heart rate variability monitoring to enable rapid determination of neurological and physiological effects of a dosage, establishing dosing levels of the biologically active agent, and/or v) defining the corresponding metabolic effects of the dosage of the biologically active agent on the subject.